TOKEN2049
8.7.2022 10:45:13 CEST | Business Wire | Press release
TOKEN2049 , Asia’s premier crypto conference, has announced a new batch of title sponsors and speakers for its upcoming Singapore edition which will be running from 28 to 29 September. This year marks the conference’s Singapore debut, making for a thrilling week of activities as some of the world’s most pioneering projects gather at what’s set to be the crypto industry’s first major in-person event in Asia ahead of the Formula 1 Singapore Grand Prix 2022 race weekend.
In recognition of growing excitement around the event, TOKEN2049 Singapore’s roster of sponsors grew to 200 firms within the last three weeks. New additions to its line-up of title sponsors include next-generation crypto spot and derivatives trading exchange OKX ; leading hardware wallet manufacturer Ledger ; one of the world’s largest crypto exchanges Kucoin ; Hong Kong-based digital asset exchange AAX ; the world’s largest cryptocurrency derivatives copy trade platform Bitget ; and homegrown Singaporean crypto exchange Coinhako, which secured its major payment institution license earlier this year.
A notable addition to this year's Title Sponsor lineup is a leading South Korean game company WEMADE , best known as the creator of leading MMORPG series Legend of Mir which sees over 120 million players worldwide. WEMADE has been servicing blockchain games since 2020, and currently 14 titles are onboarded on its platform WEMIX , including MIR4, the number 1 play-to-earn MMORPG.
A WEMADE spokesperson said: “With the industry growing at unprecedented levels and the amount of innovation it’s channeling globally, TOKEN2049 and the important conversations that it will catalyse couldn’t have come at a better time.”
As the flagship event of Asia Crypto Week , the conference is expected to draw 3,000 attendees from across the world. This year’s impressive line-up includes Stani Kulechov, Founder and CEO of AAVE, the leading open-source and non-custodial liquidity protocol; Haseeb Kureshi, Managing Partner of Dragonfly Capital; and Eli Ben-Sasson, Co-Founder and President of Starkware and co-inventor of zkSTARK, the privacy-preserving cryptographic proof.
Panels and keynotes at the event are set to address a broad agenda — from the evolving regulatory landscape and institutional investment trends to the rise of the metaverse, Web3, and what this will ultimately mean for the industry as mainstream awareness intensifies.
The Singapore event is set to be the largest in TOKEN2049’s history amid the token economy’s huge potential to transform industries and communities around the world. As a testament to growing interest among broader mainstream audiences, McLaren Racing Formula One driver Daniel Ricciardo, the new brand ambassador for world-leading crypto trading app and web3 platform OKX, will also be speaking at the conference ahead of Sunday’s Singapore Grand Prix 2022 race, sharing his views on digital assets and the evolving nature of fan engagement.
Additional speakers at this year’s conference include Justin Sun, Founder of Tron, the open-source, Proof-of-Stake blockchain platform and Sandeep Nailwal, Co-Founder of Polygon, the decentralised Ethereum scaling platform.
Commenting on the 200-sponsor milestone, Raphael Strauch, Founder of TOKEN2049 said: “The numbers don’t lie, and this overwhelming interest and energy only bode well for the industry. I’m thrilled to see the conversations and solutions that will emerge from Singapore this September.”
As part of Asia Crypto Week, attendees can expect to attend a full line-up of side events, including Pantera Blockchain Summit Asia, Milken Institute Asia Summit, and Algorand AVM Singapore, with many more to be announced in the coming weeks.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005567/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom